{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:10:40Z","timestamp":1791591040904,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.leukres.2022.106996","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T20:20:54Z","timestamp":1669839654000},"page":"106996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cytogenetic peripheral blood monitoring in azacitidine treated patients with high-risk MDS\/sAML: A monocentric real-world experience"],"prefix":"10.1016","volume":"124","author":[{"given":"Friederike","family":"Braulke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Schweigh\u00f6fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Schanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoon","family":"Shirneshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-5985","authenticated-orcid":false,"given":"Christina","family":"Ganster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrix","family":"Pollock-Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Leha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.leukres.2022.106996_bib1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00277-008-0499-3","article-title":"Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes","volume":"87","author":"Germing","year":"2008","journal-title":"Ann. Hematol."},{"issue":"13","key":"10.1016\/j.leukres.2022.106996_bib2","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","article-title":"New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients","volume":"110","author":"Haase","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2022.106996_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00277-008-0483-y","article-title":"Cytogenetic features in myelodysplastic syndromes","volume":"87","author":"Haase","year":"2008","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2022.106996_bib4","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106996_bib5","first-page":"2454","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012"},{"issue":"8","key":"10.1016\/j.leukres.2022.106996_bib6","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","article-title":"New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge","volume":"30","author":"Schanz","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2022.106996_bib7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JCO.1986.4.3.325","article-title":"Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7","volume":"4","author":"Le Beau","year":"1986","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2022.106996_bib8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.annonc.2020.11.002","article-title":"Electronic address: clinicalguidelines@esmo.org. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020\u2606","volume":"32","author":"Fenaux","year":"2021","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2022.106996_bib9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0145-2126(01)00064-9","article-title":"Increased peripheral stem cell pool in MDS: an indication of disease progression?","volume":"25","author":"Vehmeyer","year":"2001","journal-title":"Leuk. Res"},{"issue":"8","key":"10.1016\/j.leukres.2022.106996_bib10","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood.V86.8.2906.2906","article-title":"Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations","volume":"86","author":"Haase","year":"1995","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2022.106996_bib11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/sj.leu.2400638","article-title":"Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117","volume":"11","author":"Haase","year":"1997","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2022.106996_bib12","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.leukres.2010.01.010","article-title":"FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients","volume":"34","author":"Braulke","year":"2010","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.leukres.2022.106996_bib13","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.leukres.2013.03.019","article-title":"Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study","volume":"37","author":"Braulke","year":"2013","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.leukres.2022.106996_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.2014.110452","article-title":"Validation of cytogenetic risk groups according to international prognostic scoring systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group","volume":"100","author":"Braulke","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2022.106996_bib15","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1182\/blood.V95.4.1188.004k38_1188_1194","article-title":"Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age","volume":"95","author":"Deeg","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2022.106996_bib16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2009.21.8073","article-title":"Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"28","author":"Lim","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2022.106996_bib17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.22779","article-title":"Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes","volume":"110","author":"Knipp","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2022.106996_bib18","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.leukres.2022.106996_bib19","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2022.106996_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2022.106996_bib21","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2022.106996_bib22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00277-010-1015-0","article-title":"Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS study group","volume":"89","author":"G\u00f6tze","year":"2010","journal-title":"Ann. Hematol."},{"issue":"10","key":"10.1016\/j.leukres.2022.106996_bib23","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","article-title":"Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study","volume":"20","author":"Kornblith","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2022.106996_bib24","first-page":"937","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009"},{"key":"10.1016\/j.leukres.2022.106996_bib25","series-title":"ISCN 2013: An international system for human cytogenetic nomenclature (2013) recommendations of the International Standing Committee on Human Cytogenetic Nomenclature","year":"2013"},{"key":"10.1016\/j.leukres.2022.106996_bib26","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000"},{"issue":"2","key":"10.1016\/j.leukres.2022.106996_bib27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2022.106996_bib28","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00277-017-2983-0","article-title":"Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial","volume":"96","author":"Braulke","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2022.106996_bib29","series-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"10.1016\/j.leukres.2022.106996_bib30","first-page":"141","article-title":"An empirical transition matrix for non-homogeneous markov chains based on censored observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scand. J. Stat."},{"issue":"3","key":"10.1016\/j.leukres.2022.106996_bib31","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A Class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann. Stat."},{"key":"10.1016\/j.leukres.2022.106996_bib32","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2018"},{"key":"10.1016\/j.leukres.2022.106996_bib33","unstructured":"Therneau, Terry M. 2015. A Package for Survival Analysis in S. \u3008https:\/\/CRAN.R-project.org\/package=survival\u3009."},{"key":"10.1016\/j.leukres.2022.106996_bib34","unstructured":"Gray, Bob. 2019. Cmprsk: Subdistribution Analysis of Competing Risks. \u3008https:\/\/CRAN.R-project.org\/package=cmprsk\u3009."},{"issue":"6","key":"10.1016\/j.leukres.2022.106996_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.leukres.2022.106996_bib36","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/leu.2013.305","article-title":"Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS","volume":"28","author":"List","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2022.106996_bib37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/ejh.12380","article-title":"Outcomes in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study","volume":"93","author":"Giagounidis","year":"2014","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2022.106996_bib38","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","article-title":"Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine","volume":"117","author":"Itzykson","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2022.106996_bib39","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.leukres.2013.05.005","article-title":"Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment","volume":"37","author":"Douvali","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2022.106996_bib40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.leukres.2017.10.013","article-title":"Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine","volume":"63","author":"S\u00e9bert","year":"2017","journal-title":"Leuk. Res."},{"issue":"45","key":"10.1016\/j.leukres.2022.106996_bib41","doi-asserted-by":"crossref","first-page":"27882","DOI":"10.18632\/oncotarget.25328","article-title":"Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature","volume":"9","author":"Kuendgen","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.leukres.2022.106996_bib42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ajh.24650","article-title":"Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents","volume":"92","author":"Jabbour","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2022.106996_bib43","first-page":"1168","article-title":"Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes","volume":"90","author":"Sol\u00e9","year":"2005","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.leukres.2022.106996_bib44","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2012.074831","article-title":"A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial","volume":"98","author":"Gore","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2022.106996_bib45","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cancergencyto.2009.09.015","article-title":"Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome","volume":"196","author":"Wang","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"issue":"6","key":"10.1016\/j.leukres.2022.106996_bib46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00277-010-0927-z","article-title":"Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? a study on 153 patients from a single institution","volume":"89","author":"Bernasconi","year":"2010","journal-title":"Ann. Hematol."},{"issue":"21","key":"10.1016\/j.leukres.2022.106996_bib47","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1182\/blood.V118.21.968.968","article-title":"Cytogenetic clonal evolution in MDS is associated with shifts towards unfavorable karyotypes according to ipss and shorter overall survival: a study on 988 mds patients studied sequentially by chromosome banding analysis","volume":"118","author":"Haferlach","year":"2011","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2022.106996_bib48","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1002\/cncr.30917","article-title":"Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis","volume":"123","author":"Neukirchen","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2022.106996_bib49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41408-018-0061-z","article-title":"Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders","volume":"8","author":"Schanz","year":"2018","journal-title":"Blood Cancer J."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622003721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622003721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:04Z","timestamp":1758934984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622003721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":49,"alternative-id":["S0145212622003721"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106996","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytogenetic peripheral blood monitoring in azacitidine treated patients with high-risk MDS\/sAML: A monocentric real-world experience","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106996"}}